Electrical Stimulation for the Treatment of Pain and Muscle Rehabilitation (for Idaho Only)
Defines coverage and medical necessity criteria for TENS, FES, NMES and related electrical stimulation therapies for UnitedHealthcare members in Idaho, including Idaho Medicaid Plus plans.
Policy Summary
PayerUnitedHealthcare
PolicyElectrical Stimulation for the Treatment of Pain and Muscle Rehabilitation (for Idaho Only)
Policy CodePolicy CSO36ID.B
Change TypeSupporting information and references updatedprevious version archived
Effective DateAug 1, 2025
Next Review DateN/A
Key ActionProvide prior authorization and documentation of prior conservative rehabilitation and clinical criteria when requesting implantable or rehabilitative electrical stimulation.
Supporting Information Updated Clinical Evidence and References sections to reflect the most current information
Supporting Information Updated Clinical Evidence and References sections to reflect the most current information
Idaho-onlystate applicability
10+procedure and supply codes referenced
Multipletherapies listed as not medically necessary
11FES criteria count
Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.
3NMES covered indications
Coverage Criteria and Evidence Summaries
TENS — InterQual referenced coverage
Refer to InterQual for full clinical gating. TENS is considered proven and medically necessary when InterQual CP criteria are met.
TENS coverage gating: Transcutaneous electrical nerve stimulator (TENS) is covered when the member meets the medical necessity clinical coverage criteria defined by InterQual CP: Durable Medical Equipment; Transcutaneous Electrical Nerve Stimulation (TENS).
See InterQual for detailed item-level clinical requirements.
Functional Electrical Stimulation (FES) for ambulation after spinal cord injury
Covered when ALL of the following are met:
FES candidacy criteria: Member meets ALL: muscle and joint stability for weight bearing that demonstrates balance and control to maintain an upright support posture independently; intact lower motor units (L1 and below) (both muscle and peripheral nerves); brisk muscle contraction; high level of motivation, commitment, and cognitive ability for device use; sensory perception sufficient for muscle contraction; ability to transfer independently; hand and finger function to manipulate controls; independent standing tolerance for at least 3 minutes; post-recovery from spinal cord injury and restorative surgery of at least 6 months; absence of history of long bone fracture secondary to osteoporosis; absence of hip and knee degenerative disease.see individual items
FES is proven and medically necessary only for ambulation rehabilitation after SCI meeting all listed criteria; other indications are unproven and not medically necessary.
NMES is medically necessary for ANY of the following indications when documented and, where specified, used as part of a comprehensive rehabilitation program:
NMES covered indications: NMES is medically necessary for any of the following: (1) disuse muscle atrophy when the nerve supply to the muscle is intact and atrophy is non-neurological in origin (e.g., casting, splinting, contractures); (2) to improve upper extremity function in persons with partial paralysis following stroke when used as part of a comprehensive rehabilitation program (nerve supply intact); (3) when used as part of a comprehensive lower limb rehabilitation program following total knee arthroplasty (TKA).
NMES should be documented as adjunctive to standard rehabilitation where indicated; NMES for other indications is unproven and not medically necessary.
Modalities considered unproven / not medically necessary
Unproven modalities: The following modalities are considered unproven and not medically necessary due to insufficient evidence of efficacy: microcurrent electrical nerve stimulation (MENS); interferential therapy (IFT) for musculoskeletal disorders/injuries or to facilitate healing of nonsurgical soft tissue injuries or bone fractures; percutaneous electrical nerve stimulation (PENS)/percutaneous neuromodulation therapy (PNT); percutaneous peripheral nerve stimulation (PNS); percutaneous electrical nerve field stimulation (PENFS); peripheral subcutaneous field stimulation (PSFS)/peripheral nerve field stimulation (PNFS); restorative neurostimulation; pulsed electrical stimulation (PES); scrambler therapy (ST); translingual stimulation (TS) for rehabilitation gait.
See related policies for specific exceptions (e.g., occipital neuralgia, DRG, implanted stimulators).
Evidence summaries (informational)
Informational summaries of clinical evidence relevant to coverage decisions:
SCI evidence summary: Systematic reviews, cohort studies and RCTs report physiologic and functional benefits of FES/NMES in spinal cord injury including muscle hypertrophy and improved aerobic fitness with hybrid FES cycling; however, studies are small, heterogeneous, and methodologically variable, limiting generalizability.
See cited systematic reviews and cohort studies for study-level details.
Post-stroke evidence summary: For post-stroke upper limb and foot drop, multiple HTAs and meta-analyses report low-to-moderate quality evidence with inconsistent functional improvements versus AFOs or exercise; some RCTs show benefit for select devices or when combined with supervised exercise.
Evidence quality limitations include small samples, device heterogeneity, and short follow-up.
Rehabilitative device evidence caveat: Many trials used prototype or research devices; applicability to commercial devices used in clinical practice may be limited without device-specific evidence.
Consider device-specific evidence when assessing requests.
Evidence-based coverage groups
Evidence-based coverage considerations (contexts where randomized trials or systematic reviews inform potential coverage):
Stroke — upper limb: FES/CCFES/MeCFES may improve upper limb motor outcomes when used as an adjunct to conventional occupational/physical therapy, particularly in subacute–chronic stroke; overall evidence quality is low-to-mixed and benefits are device- and protocol-dependent.
Selective coverage appropriate when used within comprehensive rehabilitation and documented outcome measures are provided.
Stroke — foot drop: Peroneal nerve FES can improve ankle dorsiflexion, balance and walking speed when combined with supervised exercises; evidence is low-to-moderate quality and inconsistent versus AFOs.
Document prior conservative measures (e.g., AFO) and rationale for FES selection.
NMES — post-TKA and disuse atrophy: NMES added to rehabilitation after TKA can attenuate quadriceps weakness and improve early function with effects persisting up to one year in some trials; NMES is supported for disuse atrophy when innervation intact.
Use as part of comprehensive rehab programs; document therapy regimen and outcomes.
Contexts with evidence of benefit
Contexts where NMES showed benefit in cited studies (informational):
Supported adjunctive uses: NMES demonstrated potential benefit as an adjunct to standard rehabilitation for: (a) attenuation of quadriceps weakness and improved function after TKA, (b) prevention of muscle atrophy/strength preservation after ACL reconstruction or following immobilization, (c) improved swallowing function when combined with swallowing therapy after stroke, and (d) potential ADL improvements post-stroke in selected subgroups (subacute timing, severe paresis).evidence variable across indications
Document prior/concurrent standard rehabilitation and use validated outcome measures.
Feasibility and physiologic outcome findings
Preliminary physiologic or feasibility findings (informational):
Physiologic/feasibility signals: Small feasibility RCTs report physiologic signals with NMES such as increased femoral venous peak velocity (possible DVT prophylaxis), reduced postoperative edema, and short-term reductions in mobilization pain; these findings require larger trials for clinical outcome validation.small single-center studies
Consider physiologic endpoints exploratory unless supported by larger outcome trials.
Neurologic rehabilitation contexts
Neurologic rehabilitation contexts with mixed but potentially supportive evidence:
Neurologic/CP applications: NMES and related FES applications may improve muscle physiology, strength, gait, and selected functional outcomes in spastic cerebral palsy and post-stroke rehabilitation (upper and lower extremity) when used alongside task-oriented therapies; protocols and dosing are heterogeneous and evidence certainty is moderate-to-low.heterogeneous evidence
Coverage limited to contexts with documented standard rehabilitation and outcome monitoring.
Evidence summaries informing coverage
Evidence and guideline positions that inform coverage decisions (informational):
Stroke — motor recovery and dysphagia: Systematic reviews and RCTs indicate NMES/CCFES can improve certain motor and ADL measures post-stroke, and NMES combined with swallowing therapy can improve dysphagia outcomes; NICE recommends that transcutaneous NMES for oropharyngeal dysphagia be used only with special arrangements for governance or research due to limited evidence quality.
Prior authorization or special program enrollment may be appropriate for dysphagia indications.
IFT/IFC and musculoskeletal pain: IFT/IFC evidence is mixed; some meta-analyses show short-term pain and function benefit in knee OA and NSCLBP immediate post-treatment, but overall heterogeneity and guideline statements (NICE) recommend against offering IFT for some indications due to insufficient evidence.
IFT generally considered unproven for routine coverage in many musculoskeletal indications.
Evidence summaries relevant to coverage decisions
Key effectiveness findings and guideline conclusions (informational):
IFC and TENS evidence: Systematic reviews and RCTs show mixed comparative effectiveness between IFC and TENS across musculoskeletal conditions; some analyses identify IFC as promising for knee OA pain relief but methodological heterogeneity limits conclusions.
NICE recommends against offering IFT for knee OA and chronic primary pain due to insufficient evidence.
MENS evidence: Small RCTs and meta-analyses suggest modest pain reductions for MENS in specific conditions (e.g., masticatory myofascial pain), but trials are limited in size and duration and larger high-quality trials are needed.
Not sufficient to support broad coverage beyond documented trial contexts.
Coverage-relevant evidence groups
Coverage-relevant evidence groups (perioperative and peripheral nerve contexts):
TEAS perioperative analgesia: Transcutaneous electrical acupoint stimulation (TEAS) has RCTs and meta-analyses showing reduced postoperative pain and opioid consumption in the first 24–72 hours; benefits are generally short-term and heterogeneous across procedures.evidence supports short-term benefit
May be considered adjunctive in perioperative settings with documented protocol.
PENS for focal neuropathic conditions: PENS has RCT evidence in select peripheral neuropathic indications (e.g., CTS) showing short- to mid-term benefits; overall evidence is small and single-center in many cases.may be considered for specific peripheral nerve indications with documentation
Provider training and documentation of targeted nerve and outcomes recommended.
General coverage stance by modality
General coverage stance by modality (informational):
PENS / PENFS: Evidence is limited and of low quality for many indications; NICE recommends not offering PENS for low back pain with or without sciatica; PENS may be considered in select neuropathic conditions but broad routine coverage is not supported.
Provider competency and prior conservative therapy documentation advised.
PNS: Evidence for percutaneous peripheral nerve stimulation is evolving; small RCTs and series show benefit in some post-surgical and localized neuropathic pain settings, but overall evidence is heterogeneous and insufficient for broad routine coverage pending larger RCTs.
60-day percutaneous PNS protocols used in trials; prior conservative management expected.
PES/PEMF: PEMF/PES evidence is inconsistent and heterogeneous; some RCTs report short-term improvements in OA or postoperative recovery but results are variable and long-term data limited.
Routine coverage not supported without condition-specific evidence of sustained clinical benefit.
ReActiv8 trial-like eligibility: Patient selection aligned with trials: refractory mechanical chronic low back pain despite >90 days of medical management including at least one attempt at physical therapy; documented multifidus dysfunction (imaging or physiologic testing); not a candidate for spine surgery or SCS; baseline pain and disability documented (e.g., VAS, ODI); rationale for implantation documented.as in trials
Evidence mixed; prior conservative therapy failure is part of trial inclusion and device labeling.
PEMF/PES evidence and considerations
PEMF/PES evidence and considerations (informational):
PEMF evidence summary: Systematic reviews and RCTs report short-term improvements in pain and stiffness for osteoarthritis and some postoperative outcomes with PEMF; benefits on function may require 4–6 week regimens, but evidence is heterogeneous and long-term data are limited.variable by study
Larger, standardized RCTs with longer follow-up are needed to confirm clinical effectiveness.
Scrambler Therapy coverage considerations
Scrambler Therapy — evidence summary and considerations (informational):
Scrambler therapy evidence: Randomized trials and pilot studies report marginal short-term pain reduction and decreased analgesic consumption in some neuropathic conditions (e.g., CIPN, DPN), but studies are small, heterogeneous, often single-arm, and of low methodological quality; meta-analyses report marginal benefit at end of treatment with inconsistent longer-term effects.end of treatment to 3 months
Guidelines (ASCO, ESMO) do not recommend routine use for CIPN; consider investigational or trial-based use.
Evidence limitations: Studies limited by small sample sizes, heterogeneous devices/protocols, short follow-up, and low methodological quality, reducing confidence in long-term effectiveness.
May justify restricting routine coverage absent supportive high-quality evidence or enrollment in research.
Guideline positions: ASCO and ESMO-based guidelines do not recommend routine use of scrambler therapy for CIPN outside clinical trials due to inconsistent evidence.
Prior authorization with trial enrollment or strong rationale may be required.
TLNS evidence summary: TLNS combined with targeted physical therapy has shown improvement in gait and balance metrics in small RCTs and pilot studies in MS and mmTBI populations, but generalizability is limited by small samples, potential center effects, and variability in prior therapy exposure.
Consider investigational status; require documentation of concurrent targeted physical therapy and objective outcome measures.
Limitations: Concerns include small sample sizes, single-center trial influence, placebo and nonspecific effects, variability in prior therapy, and need for longer-term follow-up and replication.
Further high-quality multicenter RCTs recommended.
This policy section states that FES and NMES are considered medically necessary only for the specific indications and criteria listed elsewhere in the policy. Modalities not meeting those specified criteria — and several other electrical stimulation approaches — are identified as unproven and not medically necessary. Examples explicitly listed as unproven include Microcurrent electrical nerve stimulation (MENS), Interferential therapy (IFT), PENS/PNT, percutaneous peripheral nerve stimulation (PNS), PENFS, PSFS/PNFS, restorative neurostimulation, pulsed electrical stimulation (PES), scrambler therapy (ST), and translingual stimulation (TS). Providers should therefore assume services outside the listed, supported indications are not covered unless elsewhere authorized by specific plan terms or supporting evidence.
The Hayes Health Technology Assessment (HTA) updates are cited noting an overall low-quality body of evidence for rehabilitative FES in many stroke populations, with study limitations (small sample sizes, heterogeneity of devices and protocols, short follow-up) and inconsistent functional benefits compared with comparators such as ankle‑foot orthoses (AFOs). The HTA concluded additional standardized RCTs with longer follow-up are needed; given these limitations the policy treats FES efficacy for some post‑stroke populations as insufficient to support generalized coverage outside the policy’s specified FES indications.
The document highlights that many positive findings reported in the literature derive from prototype or research devices rather than widely available commercial systems. As ECRI noted, this creates uncertainty about whether trial outcomes will generalize to commercial devices used in routine clinical practice, and that device‑specific evidence should be considered when evaluating requests for coverage or prior authorization.
A systematic review in cerebral palsy populations found insufficient evidence to support botulinum toxin or masticatory muscle strengthening programs alone, or when combined with NMES, for treatment of masticatory muscle spasticity. The authors concluded clinical decisions must be individualized and that further randomized trials are needed before routine coverage can be supported.
NICE guidance and pooled systematic reviews are cited regarding NMES and IFT. NICE concluded that transcutaneous NMES should not be routinely offered for knee osteoarthritis because evidence of benefit is insufficient, and that transcutaneous NMES for oropharyngeal dysphagia should only be used with special arrangements for clinical governance or research. Similarly, NICE recommends that IFT should not be offered for knee osteoarthritis or for chronic primary pain and low back pain due to lack of consistent clinical benefit.
NICE guidance and HTA findings for percutaneous and needled approaches (PENS/PENFS) conclude evidence is limited and of low quality for chronic low back pain; NICE explicitly recommends that PENS should not be offered for low back pain with or without sciatica. Health‑technology assessments report short‑term signals in some studies but insufficient and inconsistent data to support routine coverage outside defined research or governance programs.
The policy notes that therapies relying on sparse, heterogeneous, or very low‑quality evidence—examples include certain percutaneous peripheral nerve stimulation systems and PES/PEMF for chronic pain indications—are effectively excluded from routine coverage pending stronger evidence. Systematic reviews and HTAs call for larger, well‑designed RCTs to establish efficacy and patient selection criteria before broad adoption.
ECRI and Hayes assessments are summarized as concluding that evidence is inconclusive or limited for several newer device categories; for example, restorative neurostimulation (ReActiv8) evidence remains inconclusive according to these HTAs, with recommendations for additional independent studies and longer‑term outcome reporting before routine coverage can be supported.
Guideline statements from ASCO and ESMO/EONS/EANO are cited for scrambler therapy in the setting of chemotherapy‑induced peripheral neuropathy (CIPN). Both sets of guidelines indicate scrambler therapy is not recommended in routine practice for CIPN outside clinical trials due to limited and inconsistent trial results; this guideline‑based position supports treating routine scrambler therapy for CIPN as excluded from coverage unless clinical‑trial participation or other strong justification is provided.
Implanted restorative neurostimulation (ReActiv8) is described as an FDA‑approved implantable system with an indication limited to adults with intractable chronic low back pain associated with multifidus dysfunction who have failed conservative therapies (including pain medications and physical therapy) and who are not candidates for spine surgery. Coverage considerations therefore align with trial‑like patient selection (documentation of >90 days of failed conservative care and evidence of multifidus dysfunction) and may require prior authorization and specialty provider oversight.
The cited NICE interventional guidance and other HTA sources are used throughout the document to inform coverage reasoning, but the excerpt in this section does not list additional explicit exclusions beyond the modalities and indications already identified as unproven or not medically necessary. Providers should cross‑reference the full policy for detailed exclusion language and any plan‑specific constraints.
This Medical Policy is intended to assist interpretation of UnitedHealthcare standard benefit plans for Idaho members; however, federal, state, or contractual plan requirements govern in the event of a conflict. Providers must verify the member’s specific plan terms and prior authorization requirements before arranging device implantation or therapy that may be limited by those contractual rules.
The policy identifies a set of modalities that are listed as unproven and not medically necessary. That list explicitly includes MENS, IFT for musculoskeletal disorders and injuries, PENS/PNT, percutaneous peripheral nerve stimulation (PNS) for unspecified indications, PENFS, PSFS/PNFS, restorative neurostimulation, PES, scrambler therapy, and translingual stimulation. When requesting coverage or prior authorization, providers should document how the requested therapy aligns with the policy’s supported indications and supply high‑quality supporting evidence if seeking consideration for an unlisted use.
Across the evidence summaries cited in this section, common limitations are repeatedly noted: small sample sizes, heterogeneity of devices and treatment protocols, short follow‑up, and frequent use of prototype/research devices. These limitations reduce generalizability to routine clinical practice and often result in low or very low strength of evidence determinations from HTAs and systematic reviews, forming the basis for the policy’s restricted coverage and noncoverage determinations.
Procedure, DME and Product Codes
Prior Authorization
Provider Action: Prior Authorization, Documentation, and Coverage Considerations
Prior authorization and documentation: Providers should obtain prior authorization when required by the plan for FES, NMES, percutaneous or implantable peripheral nerve stimulation (PNS), and implantable neurostimulator systems. Prior authorization requirements depend on plan terms and device labeling; inclusion of a code in this section does not itself authorize coverage.
Prior authorization is commonly required for FES/NMES devices and for percutaneous or implantable PNS — verify plan-specific prior authorization rules before proceeding.
Special arrangements or prior authorization may be necessary for NMES used to treat dysphagia (if considered by the plan).
Prior authorization is implied by device labeling or FDA indication in some cases; providers must reference current FDA indications when seeking authorization.
Prior authorization depends on plan terms; absence of a prior authorization statement in this section does not mean prior authorization is not required by the member's contract.
When prior authorization is required, submit medical records documenting prior conservative therapy, duration, objective outcomes, and trial results (e.g., prior therapy and outcome documentation).
Prior Authorization, Documentation, and Clinician Guidance
Prior Authorization
Prior authorization recommended for implantable and rehabilitative devices
For implanted restorative neurostimulation systems and implanted or rehabilitation FES systems, prior authorization is generally appropriate; provide diagnosis, prior conservative therapy, and functional impairment documentation when requesting coverage.
Restorative neurostimulation (e.g., ReActiv8) is an implantable device—document failed conservative therapy and rationale per device labeling.
FES used as part of comprehensive ambulation rehab for SCI requires meeting detailed clinical criteria; implantation warrants review prior to procedure.
Prior Authorization
Prior authorization: include device type, indication, and prior therapies
When requesting FES or NMES services, include device type, indication (e.g., foot drop after stroke or MS), prior conservative therapies tried, and planned duration/frequency of therapy in the authorization request.
For FES: document that all FES candidacy criteria are met when used for SCI ambulation per policy.
For NMES: specify that NMES will be used as part of a comprehensive rehabilitation program when indicated.
Conservative Care and Prior Treatment Documentation
inv-155: Use as part of a comprehensive rehabilitation program is required for NMES in stroke upper extremity and post-TKA lower limb rehabilitation indications.
NMES rehabilitation requirement: Use of NMES for post-stroke upper extremity rehabilitation and for early post-TKA quadriceps rehabilitation is required to be part of a comprehensive rehabilitation program to be considered medically necessary.
Document concurrent standard rehabilitation program in medical records.
inv-156: Document prior rehabilitation efforts and functional deficits before implantable or rehabilitative electrical stimulation is considered.
Prior rehabilitation documentation: Document prior rehabilitation efforts and specific functional deficits (e.g., foot drop, quadriceps weakness) before considering implantable or rehabilitative electrical stimulation interventions.
Include therapy type, duration, frequency, objective outcome measures, and response to prior treatments.
Treatment Frequency, Duration and Program Examples
inv-167: FES therapy programs — program durations in trials varied (e.g., 6 weeks FES training in CHF; 25 sessions of 45 minutes in MeCFES trial)
CHF FES programSix-week FES training program reported in CHF RCT with follow-up up to 19 months (Kadoglou et al. 2017)
MeCFES dosingMeCFES RCT delivered 25 sessions of 45 minutes each (Jonsdottir et al. 2017)
Trial program variabilityProgram durations in FES trials varied by indication and study protocol
inv-168: PENS / TEAS — examples of dosing schedules across studies
PENS (CTS) exampleUltrasound‑guided PENS once weekly for three weeks targeting the median nerve (Fernandez‑de‑Las‑Penas trial)
TEAS perioperative exampleTEAS administered perioperatively and in PACU with multiple RCTs showing reduced opioid consumption over first 24–72 hours
Imaging and Procedural Guidance Notes
Billing Rule
Spinal neurostimulator implantation/revision — fluoroscopy as indicated
Fluoroscopy is included in CPT descriptions for spinal neurostimulator electrode implantation and revision codes; imaging guidance (fluoroscopy) should be used as indicated during these implant/revision procedures.
CPT descriptors for 63663 and 63664 include ‘including fluoroscopy, when performed’—document imaging use when applicable.
Note
FES/NMES — no routine imaging specified
No specific imaging guidance is specified for FES or NMES in the policy — routine imaging is not required for these noninvasive rehabilitation modalities unless otherwise indicated.
FES and NMES trials generally report functional assessments rather than imaging requirements.
Definitions and Modality Descriptions
inv-111: FES definition
DefinitionFunctional Electrical Stimulation (FES): direct application of electric current to intact nerve fibers in a coordinated fashion to cause involuntary but purposeful contraction
Delivery methodsElectrodes may be surface‑placed or surgically implanted; used for therapeutic (exercise/conditioning) or functional (enable movement) goals
Mechanism focusBypasses central nervous system to target motor neurons to produce functional contractions
inv-112: NMES definition
DefinitionNeuromuscular Electrical Stimulation (NMES): transcutaneous application of electrical currents to cause muscle contractions to promote reinnervation, prevent disuse atrophy, relax spasms, and promote voluntary muscle control
Indications context
Policy Update and Versioning
Note
Material change — policy references and evidence updated (08/01/2025)
Supporting references and the policy version were updated effective 08/01/2025; archived/superseded prior versions may not reflect current evidence—use the current policy and reference list when preparing authorizations.
Policy history indicates Supporting Information and References were updated and previous version CSO361D.A was archived.
Denial Risk
Policy update/versioning risk — verify effective policy version before submission
Policy updates and versioning can affect coverage and authorization decisions; claims submitted under superseded guidance without meeting updated criteria may be denied—confirm the effective policy version prior to submission.
Verify that documentation aligns with the effective date and updated clinical evidence cited in the current policy.
Policy Summary
PayerUnitedHealthcare
PolicyElectrical Stimulation for the Treatment of Pain and Muscle Rehabilitation (for Idaho Only)
Policy CodePolicy CSO36ID.B
Change TypeSupporting information and references updatedprevious version archived
Effective DateAug 1, 2025
Next Review DateN/A
Key ActionProvide prior authorization and documentation of prior conservative rehabilitation and clinical criteria when requesting implantable or rehabilitative electrical stimulation.
Conservative therapy is expected before neuromodulation procedures in many cases (e.g., conservative-first guidance) though this policy does not establish a hard step-therapy sequence; document attempts and outcomes of conservative measures.
For percutaneous or implantable PNS, documentation of prior conservative therapy is typically required before approval.
Clinical outcome and safety documentation, including functional outcomes and adverse events, should be included with requests when applicable.
Clinical trial outcomes, comparators, and follow-up data (durability, safety) may be requested to support coverage decisions for newer or limited-evidence devices.
Insufficient or limited evidence (for example, low back pain or PES/PEMF therapies in some indications) may lead to denial; document rationale and supporting evidence when requesting authorization.
There is no explicit procedural or billing authorization in this section; billing must follow applicable code definitions and payer rules.
Medical records are required for review; the policy may request specific items such as prior therapy trials, objective measures, and device training or rehabilitative program participation.
Use updated references for device approvals and product codes (FDA listings) when submitting documentation; policy cites FDA product codes for many devices.
NMES may be considered an adjunctive therapy to supervised therapeutic exercise programs for some device indications (e.g., PoNS); document adjunctive program participation.
Policy updates and versioning risk: device approvals and coding guidance change; confirm current codes and coverage policy at time of authorization/claim.
No explicit procedural or billing author is provided in this section; contact payer for clarifications on claim submission or prior authorization processes.
Prior Authorization
Prior authorization advisable for NMES when used as adjunct to rehabilitation
Prior authorization is reasonable for NMES when used for indications with potential benefit (for example, NMES combined with swallowing therapy for post-stroke dysphagia or early quadriceps rehabilitation after TKA); submit planned protocol and evidence of concurrent standard rehab.
NMES plus swallowing therapy showed benefit in multiple RCTs/meta-analyses — document combined therapy plan and treatment course.
NMES after TKA is typically studied as adjunctive to standard rehab — include rehabilitation details and timing.
Prior Authorization
NMES for dysphagia — governance/research arrangements required
Transcutaneous NMES for oropharyngeal dysphagia should only be used with special arrangements for clinical governance, consent and audit or research per NICE — prior authorization or program enrollment may be required.
NICE indicates this technology should be used only under special arrangements for governance, consent and audit or research.
Note
No single prior authorization rule specified — follow plan processes
This section of the policy provides evidence summaries and device listings but does not define a uniform prior authorization list; follow UnitedHealthcare Idaho prior authorization processes and plan-specific rules for authorization requirements.
Policy is informational—check member’s federal, state, or contractual benefit plan for prior authorization rules.
UnitedHealthcare may use third-party tools (e.g., InterQual) to assist in administering benefits.
Prior Authorization
Prior authorization recommended to confirm indication and provider training
Given variable evidence quality and procedural/specialty training requirements (e.g., PENS), prior authorization is recommended to confirm indication, provider competency, and trial of conservative therapy before approving procedures.
AAOS notes PENS requires a trained practitioner—authorization can confirm provider training/credentialing.
Use authorization to document conservative care attempts and rationale for the proposed intervention.
Prior Authorization
Prior authorization required for percutaneous/implantable PNS — justify implantation
Prior authorization is likely required when percutaneous or implantable peripheral nerve stimulation (PNS) is proposed; submit documentation of prior conservative management, planned lead placement, and intended treatment duration (trial and implant details).
Provide evidence of failed multimodal conservative therapy prior to implantation.
Prior Authorization
Prior authorization — document failed conservative therapy for restorative neurostimulation
For implantable restorative neurostimulation requests, prior authorization should include documentation of failure of conservative therapy (including >90 days of management and at least one physical therapy attempt) and rationale aligning with trial populations.
ReActiv8 trials required >90 days of prior medical management and at least one physical therapy attempt.
Document multifidus dysfunction as indicated by imaging or physiological testing when applicable.
Prior Authorization
Prior authorization recommended for scrambler therapy — justify with trial enrollment or rationale
Because guidelines advise against routine use of scrambler therapy outside clinical trials for some indications, prior authorization is recommended and should be supported by clinical trial enrollment or a strong rationale.
ASCO and ESMO guidance do not recommend routine ST for CIPN — authorization should document trial enrollment or compelling justification.
Prior Authorization
Prior authorization: follow FDA device labeling and indicated patient selection
When device use is tied to FDA-labeled indications (for example, ReActiv8), adherence to labeled indications implies that prior authorization support should reference device labeling and patient selection criteria.
Follow FDA-approved indications and patient-selection criteria in documentation submitted for authorization.
Providers should follow UnitedHealthcare Idaho prior authorization procedures and reference the updated clinical evidence when submitting requests; the policy excerpt contains no single uniform authorization process.
Check the member’s federal, state, or contractual benefit plan for plan-specific authorization rules.
Reference updated Clinical Evidence and References when justifying medical necessity.
Note
Prior authorization depends on plan-specific terms — confirm member benefits
Prior authorization requirements may vary by the member’s plan—confirm federal, state, or contractual benefit plan terms as they govern coverage and authorization procedures.
This Medical Policy is informational; plan terms control in the event of conflict.
Note
Clinical-criteria gating — demonstrate member meets modality-specific criteria
Coverage for electrical stimulation is gated to specific clinical criteria (for example, InterQual for TENS; explicit FES and NMES criteria in this policy); authorization and documentation must demonstrate that the member meets those criteria.
FES for SCI requires meeting all listed candidacy elements (e.g., independent standing ≥3 minutes; ≥6 months post-recovery).
NMES indications require nerve supply intact and use as part of comprehensive rehabilitation when specified.
Step Therapy
Conservative-step considerations for foot drop — document AFO/trial of conservative care
For foot drop cases, document prior conservative measures such as ankle-foot orthosis (AFO) use or supervised exercise programs, or provide rationale for selecting FES over AFOs when seeking authorization.
Hayes HTA highlighted comparisons between FES and AFOs—authorization should include prior AFO trial or justification for FES.
Step Therapy
NMES use should be documented as adjunctive to standard rehabilitation
NMES is typically studied and recommended as an adjunct to standard rehabilitation (e.g., swallowing therapy, therapeutic exercise); authorization should document planned concurrent or prior standard rehab.
Meta-analyses showed benefit for NMES when combined with swallowing therapy—include therapy details and treatment course in the request.
Step Therapy
Rehabilitation-first approach for COPD — document pulmonary rehab before NMES
For COPD-related NMES requests, document prior or concurrent standard pulmonary rehabilitation—NMES should not be used as a replacement for pulmonary rehab and is considered adjunctive.
Systematic reviews conclude NMES is not a substitute for pulmonary rehabilitation; include evidence of prior rehab attempts or rationale for adjunctive NMES.
Step Therapy
Conservative-first guidance for LBP — document conservative care before ES
Clinical guidelines recommend initiating nonpharmacologic and conservative therapies for low back pain first; this policy excerpt does not mandate a fixed step-therapy sequence but expects documentation of conservative care attempts.
ACP and NICE guidance emphasize conservative therapies as first-line; include documentation of these measures in authorization requests for ES in LBP.
Step Therapy
Require documented trial of conservative therapy (typical 30–90 days) before certain ES interventions
Many studies and guideline excerpts emphasize a documented trial of conventional rehabilitation (typically 30–90 days in trials) or analgesic management before approving MENS, PENS, TEAS or similar interventions.
Use prior therapy dates, duration, and objective response measures when submitting authorization requests.
Minimum trial durations reported in studies often range from 30 days up to >90 days depending on indication.
Step Therapy
Document failed multimodal conservative therapy before PNS implantation
Prior conservative management and multimodal therapy failure should be documented before considering percutaneous or implantable PNS; trials generally enrolled patients after failure of noninvasive options.
PNS trials typically followed multimodal conservative management—include prior meds, PT, injections, and response.
Step Therapy
Conservative therapy expected before restorative neurostimulation — document >90 days failed care
Restorative neurostimulation (ReActiv8) studies required failure of conventional management including physical therapy and medications (>90 days); authorization for implantation should document these prior attempts and lack of adequate response.
ReActiv8 trial enrollment required >90 days of prior medical management and at least one attempt at physical therapy.
Step Therapy
Document prior conservative treatments before neuromodulation like scrambler therapy
Before considering neuromodulation such as scrambler therapy, document prior conservative treatments (pharmacologic agents, physical therapy) given limited and heterogeneous evidence for ST.
ST studies typically compared to sham or conventional care—include prior treatments and rationale in authorization.
Documentation Required
Medical records may be required — retain full documentation
Maintain complete medical records and supporting documentation for coverage review; medical records may be required to demonstrate the member meets clinical criteria for electrical stimulation services.
Medical records should include diagnoses, prior therapy details, objective outcome measures, and treatment plans.
Suggested documentation to support authorization includes time-since-injury or stroke, specific functional deficits (e.g., foot drop, quadriceps weakness), prior rehabilitation efforts, and objective baseline measures used in trials.
Include dates of injury/stroke, details of prior PT/OT, assistive device trials (e.g., AFO), and baseline functional scores.
For MeCFES, document stroke phase (acute/subacute/chronic), task-oriented therapy details, session duration/number, and baseline/follow-up ARAT and FMA-UE scores to support medical necessity.
Trials used 25 sessions of 45 minutes with ARAT and FMA-UE outcome measures—include comparable rehab regimen and assessment schedule.
Documentation Required
FES in CHF documentation — NYHA class, LVEF, program duration, hospitalization outcomes
For FES programs in chronic heart failure, include NYHA class, LVEF, program duration, and hospitalization outcomes when available to support claims of benefit from FES training.
Kadoglou et al. reported six-week FES training with follow-up for HF-related hospitalizations—document program details and outcomes.
Documentation Required
Suggested documentation to support NMES use — diagnosis, rehab details, outcome measures
To support NMES requests, include diagnosis, prior/concurrent standard therapy (e.g., swallowing therapy), treatment course/duration, and objective outcome measures consistent with trial protocols.
NMES plus swallowing therapy trials report treatment courses from two to 12 weeks—provide planned course and expected measures.
Document baseline and follow-up outcome measures and safety events (e.g., pain scores, opioid MME, device-related adverse events) when reporting clinical outcomes for implantable or percutaneous devices.
Restorative neurostimulation studies reported VAS, ODI, opioid reductions and adverse events—include comparable metrics.
Documentation Required
Document trial outcomes, comparators, and study limitations when justifying use
When citing clinical trial evidence to support an authorization, document trial outcomes, comparators, limitations (sample size, follow-up duration, heterogeneity, blinding) so reviewers can evaluate applicability to the member.
Trials frequently limited by small sample sizes and heterogenous devices/protocols—acknowledge these limitations in justification.
Documentation Required
Procedure documentation for PENS — indication, prior care, nerve targeted, session schedule, and outcomes
For PENS procedures (e.g., ultrasound-guided median nerve PENS for CTS), document indication, prior conservative treatments, targeted nerve, number/timing of sessions, and outcomes at baseline and follow-up (1, 3, 6, 12 months as reported in trials).
Fernandez-de-Las-Penas trial reported assessments at 1, 3, 6 and 12 months—provide comparable outcome schedule.
Documentation Required
Document prior therapy and outcome measures for PNS requests
Include details of prior multimodal management and objective outcome measures (pain scores, opioid MME) when reporting PNS outcomes or requesting authorization for PNS implantation.
PNS studies reported opioid reductions and predefined responder thresholds—document baseline opioid use and subsequent changes.
Documentation Required
Document clinical outcomes and device safety history for implantable devices
Ensure clinical outcome and safety documentation is available for device requests; restorative neurostimulation studies reported serious adverse events (including pocket infections requiring removal) and opioid use changes—include such data if relevant.
Report any prior device-related adverse events or reasons for explant when relevant to authorization.
Documentation Required
Suggested documentation elements for ST/TLNS — protocol, prior treatments, objective measures
Suggested documentation elements for investigational modalities (ST/TLNS) include indication, prior conservative treatments, planned protocol (number/duration of sessions), and objective outcome measures because literature emphasizes small samples and short follow-up.
Scrambler Therapy typical course: ~10 sessions over two weeks—provide planned session schedule and follow-up assessments.
TLNS/PoNS studies combine stimulation with targeted PT—document concomitant therapy plan.
Documentation Required
Use updated evidence and references when justifying medical necessity
Use the most recent Clinical Evidence and References when justifying medical necessity; the policy’s references and evidence base have been updated and older archived versions may not reflect current guidance.
Policy History notes updated Clinical Evidence and References as of 08/01/2025—cite current references in authorization documentation.
Note
Confirm plan-specific requirements before authorization and billing
Confirm plan-specific prior authorization, coverage, and billing requirements before submitting claims; this policy is informational and plan contractual terms govern.
UnitedHealthcare may use third-party tools (e.g., InterQual) to assist in administering benefits—follow plan procedures for prior auth submissions.
Denial Risk
Documentation-triggered denials — include required medical records
Claims or requests lacking required medical records or documentation showing the member meets the policy’s clinical criteria may be denied — include complete records to avoid documentation-triggered denials.
Medical records should demonstrate that explicit modality-specific criteria are met (e.g., FES candidacy elements, NMES rehab plan).
Denial Risk
Insufficient evidence may trigger denial — provide robust supporting documentation
Insufficient or low-quality evidence for some indications (e.g., FES for certain stroke populations) may lead to coverage denial or requests for additional documentation; provide robust supporting data when coverage is based on limited evidence.
Hayes HTA noted low-quality evidence and inconsistent benefit for FES in some stroke populations—authorization should address applicability to the member.
Denial Risk
ICU ES justification — document rationale due to lack of demonstrated benefit
When requesting ES in ICU or critically ill patients, document the clinical rationale and expected benefit since trials (e.g., early in-bed cycling plus ES) did not show improved global muscle strength at ICU discharge.
Fossat et al. found no improvement in global muscle strength from adding ES to standardized early rehabilitation—justify use with specific clinical goals.
Denial Risk
Evidence limitations may affect coverage for experimental indications
Use of NMES or other modalities for indications with limited or experimental evidence may result in non-coverage; include high-quality supporting evidence or trial enrollment information when available.
Many NMES studies are small and heterogeneous—authorization should document why NMES is appropriate for the member.
Denial Risk
Governance/research requirement for NMES in dysphagia — use may require special arrangements
NICE recommends that transcutaneous NMES for oropharyngeal dysphagia be used only with special arrangements for governance, consent and audit or research—use outside such arrangements may be denied or require documentation of research oversight.
Include evidence of participation in a governance/research program or justification aligned with NICE recommendations when seeking coverage.
Note
No explicit billing/authorization rules in this section — follow plan procedures
This document segment primarily summarizes evidence and device references and does not itself set explicit procedural or billing authorization rules; follow plan-specific authorization and billing guidance.
Policy provides clinical and evidentiary context—refer to payer procedures for submission and billing rules.
Denial Risk
Insufficient evidence for PENS in LBP — potential denial risk
Insufficient evidence for PENS in low back pain per NICE may lead to denial for that indication; do not assume routine coverage for PENS in LBP without compelling documentation or trial evidence.
NICE concluded PENS should not be offered for LBP with or without sciatica due to insufficient evidence—authorization requests should address this guidance.
Denial Risk
Insufficient evidence -> potential denial for unsupported procedures
Procedures lacking sufficient supporting evidence (for example many PNS indications) may be denied; include comparative trial data or rationale when requesting coverage for such procedures.
Recent assessments note small RCTs and limited generalizability for many PNS uses—authorize only with strong supporting documentation.
Denial Risk
Limited evidence for PES/PEMF — coverage may be denied absent robust trials
PES/PEMF modalities have limited and heterogeneous evidence; treat requests as potentially experimental and expect denials or requests for additional evidence without strong supportive data.
Policy states more robust RCTs are needed to support PES/PEMF efficacy—include high-quality evidence if available.
Denial Risk
Insufficient evidence may trigger denial — align requests with trial populations
ECRI and HTA findings showing inconclusive or limited evidence (e.g., for ReActiv8, PEMF) may lead to coverage denial or requests for additional documentation; ensure submissions align with trial populations and device indications.
ECRI concluded evidence for ReActiv8 remains inconclusive—authorization should document conformity to trial-like selection criteria if claiming benefit.
Denial Risk
Guideline-based denial risk for scrambler therapy — justify with trial enrollment
Guideline recommendations against routine scrambler therapy for CIPN or low-quality evidence mean requests for ST should be justified by clinical trial enrollment or exceptional rationale to avoid denial.
ASCO and ESMO guidelines advise against routine ST for CIPN—authorization requests should document clinical trial participation or strong rationale.
Denial Risk
Policy update/versioning risk — use current policy and references
Updates to the policy and archiving of previous versions may affect coverage determinations; claims submitted under superseded guidance without meeting updated criteria may be denied — reference the policy effective date and recent revisions.
Policy History notes Supporting Information and references were updated effective 08/01/2025—use current policy when preparing authorizations/claims.
Note
Follow contractual/federal/state requirements — plan terms govern
Follow federal, state, and contractual benefit plan requirements; in case of conflict between this medical policy and plan terms, the plan/contractual rules govern coverage and authorization decisions.
Confirm Idaho Medicaid or other plan-specific supplier/provider rules when applicable.
Conservative measures (unspecified): Document conservative therapy attempts appropriate to the condition prior to approval as applicable (see detailed conservative requirement nodes).
Placeholder for unspecified conservative nodes.
inv-158: Document prior or concurrent standard rehabilitation when requesting NMES
Document standard rehabilitation with NMES: When requesting NMES, document prior or concurrent standard rehabilitation (e.g., swallowing therapy for dysphagia, task-oriented occupational/physical therapy for stroke, standard TKA rehab) including regimen, duration, and outcome measures.
NMES studied largely as adjunct; NMES as sole therapy for these indications is not supported.
inv-159: Document prior or concurrent standard rehabilitation when using NMES or IFT for these conditions.
Document rehab for NMES/IFT: Document prior or concurrent standard rehabilitation when NMES or IFT is requested for COPD, low back pain, or other conditions where guideline-based rehabilitation is first-line; NMES/IFT should be adjunctive, not a replacement for established programs.
Provide rationale if device is requested in lieu of standard rehabilitation.
inv-160: Conservative nonpharmacologic therapies are first-line per guideline excerpt; no specific duration specified in this section.
Conservative-first guidance: For chronic low back pain and similar conditions, conservative nonpharmacologic therapies (exercise, multidisciplinary rehabilitation) are first-line per guideline excerpts; document trials of these therapies prior to considering electrical stimulation interventions.
No specific minimum duration specified in guideline excerpt; see condition-specific nodes for typical study durations.
inv-161: Documented trial of conservative therapy appropriate to condition (e.g., physiotherapy for LBP) prior to approval
Minimum documented conservative trial: Documented trial of conservative therapy appropriate to the condition (e.g., therapeutic exercise for LBP) is expected prior to approval; studies commonly used minimum 30 days and typical rehabilitation courses ranged 30–90 days.>= 30 days (typical 30–90 days)
Provide documentation of therapy type, frequency, duration, and objective outcomes.
inv-162: Document prior multimodal management and failed conservative therapy before considering percutaneous or implantable stimulation.
Document failed multimodal management: Document prior multimodal management and failed conservative therapy (pharmacologic and nonpharmacologic) before considering percutaneous or implantable stimulation interventions.
Include details of medications, physical therapy, injections, and functional outcomes.
inv-163: Document failed medical management and attempt(s) at physical therapy
Document failed medical management and PT attempts: For restorative/implantable neurostimulation and similar device-based interventions, document failure of medical management and attempts at physical therapy for a duration consistent with trials (commonly >90 days).>90 days
Provide objective measures of inadequate response and functional impairment.
inv-164 (placeholder): unspecified
Conservative placeholder: Placeholder for unspecified conservative-treatment-related criteria or notes.
No additional detail in brief.
inv-165: Failure of conservative therapies is part of the FDA-indicated patient selection for this implanted restorative neurostimulator.
ReActiv8 conservative-failure requirement: Failure of conventional therapies (including medications and physical therapy) is part of the FDA-indicated patient selection and trial inclusion criteria for the implanted restorative neurostimulator (ReActiv8) and should be documented prior to consideration of implantation.
Document duration (>90 days), therapies tried, and objective outcome measures.
inv-166
Conservative final placeholder: No additional conservative-treatment nodes specified in this excerpt.
Refer to condition-specific nodes and device labeling for exact requirements.
PENS/TENS immediate effectsPENS and TENS studies often used single or short series of sessions with immediate to short‑term outcome assessments
inv-169: percutaneous PNS — 60-day treatment course described in multiple studies
Common trial course60‑day percutaneous PNS treatment course described in multiple randomized and prospective studies
Typical daily use in studiesLeads left in place for eight weeks with daily usage prescribed (e.g., 6–12 hours/day in some series)
Follow-up reportingStudies reported outcomes up to 12–14 months after 60‑day PNS in several cohorts
inv-170: ReActiv8 restorative neurostimulation — implantable device delivers sessions twice daily as programmed; follow-up assessments at 120 days and up to years reported
Initial follow-up intervalPrimary trial delivered twice‑daily stimulation for 120 days before unblinding assessments
Long-term assessmentFollow‑up data reported at 1 year and up to 5 years in longitudinal studies (Gilligan et al.)
inv-171: Scrambler Therapy — Typical course documented as ~10 sessions over two weeks (daily on working days)
Typical course lengthApproximately 10 sessions delivered over two weeks (daily on working days) in many ST protocols
Session durationSessions typically 30–50 minutes each per trial descriptions
Follow-up windowOutcomes commonly assessed at end of treatment and up to 1–3 months thereafter
inv-172: 60-day percutaneous PNS (duration noted in trials, not a coverage frequency limit)
Trial‑noted duration60‑day percutaneous PNS course described in randomized and prospective studies (trial duration noted in evidence but not a policy frequency limit)
Protocol variabilityStudy protocols varied in hours/day of stimulation and follow‑up schedules; duration in trials should not be interpreted as a mandatory coverage frequency limit
Documentation expectationWhen requested for coverage review, cite trial course and outcomes but clarify that trial durations are evidence examples, not coverage limits
Note
NMES/CCFES — no imaging specified in trials
NMES and CCFES studies do not specify routine imaging requirements; authorization and billing generally do not require imaging documentation for these modalities.
Trials used functional outcome measures and therapy sessions rather than imaging to document therapy.
Note
MENS — no routine imaging specified (outcome assessment focus)
Microcurrent (MENS) outcome assessments in trials did not require routine imaging; include clinical outcome measures rather than imaging when documenting MENS use.
Lawson et al. used ultrasound for effusion assessment in a knee trial, but routine imaging is not specified for MENS coverage.
Billing Rule
PENS — use ultrasound guidance when described in study/procedure
When PENS studies describe ultrasound guidance for needling, document use of ultrasound guidance in procedure notes; otherwise routine imaging is not specified.
Fernandez-de-Las-Penas trial used ultrasound-guided PENS targeting the median nerve—document imaging guidance when performed.
Billing Rule
PENFS/PNS — no routine imaging specified; cite imaging if used
Policy excerpts do not specify routine imaging requirements for percutaneous electrical nerve field stimulation (PENFS) or implantable PNS procedures, though some CPT descriptors reference imaging guidance when performed.
CPT codes for peripheral nerve electrode insertion note ‘including imaging guidance, when performed’—document imaging if used.
Note
ReActiv8 implantation — imaging not explicitly required in policy excerpt
Policy does not explicitly state imaging requirements for ReActiv8 implantation in this section; follow device labeling and surgical best practices and document imaging if used intraoperatively.
ReActiv8 is an implanted restorative neurostimulation system—document perioperative imaging if used to confirm lead placement.
Note
Scrambler Therapy — no routine imaging; research imaging investigational
Scrambler Therapy trials referenced did not require routine imaging; imaging used in research settings (e.g., MRI) is investigational and not a routine billing requirement.
Some ST research used MRI for mechanistic studies—document only if performed as part of an investigational protocol.
Documentation Required
Restorative neurostimulation — image/physiologic testing may be required to document multifidus dysfunction
Restorative neurostimulation device candidacy may require imaging or physiological testing to document multifidus dysfunction per device indication; include such documentation when requesting authorization for ReActiv8.
FDA indication for ReActiv8 cites multifidus dysfunction evidenced by imaging or physiological testing—attach supporting tests if available.
Note
Guideline references included — no additional imaging requirements specified here
Guideline documents (e.g., NICE) are cited for context; this excerpt does not state additional explicit imaging requirements beyond those described above.
When guidelines suggest specialized evaluation (e.g., for dysphagia governance), follow those guidance statements and document accordingly.
Used when innervation to muscle is intact and as adjunct to rehabilitation for specific indications
inv-113: IFT definition
DefinitionInterferential Therapy (IFT/IFC): delivery of two medium‑frequency pulsed currents via skin electrodes producing a low‑frequency current theorized to penetrate deeper tissues for pain relief
Device codesIFT devices referenced via FDA product code LIH in device listings
inv-114: MENS definition
DefinitionMicrocurrent Electrical Nerve Stimulation (MENS): delivers microampere‑range currents intended for pain relief and wound healing; stimulus is sub‑sensory and distinct from TENS
Evidence noteEvidence comprises small RCTs and case series; conclusions limited by small sample sizes and heterogeneity
PENSPercutaneous Electrical Nerve Stimulation — needle‑based percutaneous electrodes connected to external stimulator; used for musculoskeletal and neuropathic pain
PENFSPercutaneous Electrical Nerve Field Stimulation — low‑frequency field stimulation often applied auricularly or to a pain field
PNSPercutaneous Peripheral Nerve Stimulation — percutaneous or implantable leads placed adjacent to a peripheral nerve for neuromodulation
PESPulsed Electrical Stimulation — external electromagnetic/electrical fields proposed to affect bone/cartilage repair and inflammation
inv-116: PSFS / PNFS definition
DefinitionPSFS / PNFS: electrode arrays implanted in subcutaneous tissue of painful area targeting cutaneous nerve endings rather than discrete peripheral nerves
Distinguishing featureUsed when painful field is ill‑defined or not confined to one or two peripheral nerves
inv-117: PES definition
DefinitionPES: Pulsed Electrical Stimulation — hypothesized to facilitate bone/cartilage repair and alter inflammatory cell function via electrostatic/electrodynamic fields
Evidence summarySystematic reviews report heterogeneous results and insufficient evidence for many chronic pain indications
inv-118: Restorative neurostimulation definition
DefinitionRestorative neurostimulation: implantable system stimulating lumbar multifidus (e.g., ReActiv8) via leads near the medial branch of the dorsal ramus to rehabilitate multifidus dysfunction in chronic mechanical low back pain
Device exampleReActiv8 Implantable Neurostimulation System (PMA; Product Code QLK)
inv-119: Scrambler Therapy definition
DefinitionScrambler Therapy (ST): noninvasive transdermal therapy applying variable nonlinear electrical waveforms to dermatomal electrode placements presenting 'non‑pain' information to painful areas
Typical protocolOften delivered as ~10 sessions of 30–50 minutes over two weeks in many trials
inv-120: TENS definition
DefinitionTENS: Transcutaneous Electrical Nerve Stimulation — low‑voltage surface electrode current intended to decrease pain perception by inhibiting afferent transmission and/or stimulating endorphin release
Regulatory statusTENS devices are FDA Class II (product codes GZJ, NUH, NGX) and are widely available
inv-121: TLS definition
DefinitionTLS / PoNS: Translingual Stimulation — noninvasive stimulation of trigeminal and facial cranial nerve inputs (via tongue device) intended to promote neuroplasticity alongside physical therapy for gait and balance deficits
Evidence noteECRI assessment and RCTs report mixed results; used as adjunct to targeted PT in trials
inv-122: FES definition (duplicate)
Definition duplicateFunctional Electrical Stimulation (FES): coordinated electrical stimulation to cause purposeful contraction; used therapeutically and functionally
inv-123: CCFES definition
DefinitionCCFES: Contralaterally Controlled FES — FES in which movement of the unaffected limb controls stimulation of the affected limb; studied for upper extremity post‑stroke recovery
Evidence noteRCTs show some improvement in manual dexterity versus cyclic NMES in selected subgroups
inv-124: MeCFES definition
DefinitionMeCFES: Myoelectric continuous control FES — FES controlled by myoelectric signals used as an adjunct to task‑oriented therapy
Dosing exampleMeCFES RCT delivered 25 sessions of 45 minutes each in both arms
inv-125: NMES definition
Definition duplicateNMES: transcutaneous electrical currents to cause muscle contractions for reinnervation, preventing disuse atrophy, and promoting voluntary control
Swallowing therapy (ST)Conventional therapeutic exercises and interventions to improve swallowing function, frequently used in combination with NMES in dysphagia trials
inv-128: CCFES definition (duplicate)
CCFES duplicateContralaterally controlled FES where unaffected limb movement controls stimulation of paretic limb; studied in stroke rehab
inv-129: IFT definition
IFT duplicateInterferential Therapy: medium‑frequency currents producing low‑frequency interference current; used for musculoskeletal pain though evidence is limited
inv-130: IFC definition
IFCInterferential Current (IFC): medium‑frequency transcutaneous stimulation studied in knee OA and other musculoskeletal conditions; trials show mixed short‑term benefit
inv-131: Microcurrent definition
MicrocurrentMicrocurrent electrical nerve stimulation (MENS): very low‑intensity currents investigated for myofascial pain, knee pain and wound healing; evidence limited
inv-132: TENS definition (duplicate)
TENS duplicateTranscutaneous Electrical Nerve Stimulation: low‑voltage surface electrode stimulation to modulate pain; often compared to IFC and sham in RCTs
inv-133: Frequency-specific microcurrent (FSM)
FSMFrequency‑specific microcurrent (FSM): proprietary microcurrent adjunct used in retrospective analyses with limited controlled evidence
inv-134: MENS (duplicate)
MENS duplicateMicrocurrent Electrical Nerve Stimulation (MENS) — low‑level microcurrent applied via electrodes for pain and function improvements; limited RCT evidence
inv-135: PENS definition
PENS definitionPercutaneous Electrical Nerve Stimulation — needle‑based percutaneous probes connected to external stimulator targeting nerves or tissues; evidence limited and variable
inv-136: TEAS definition
TEAS definitionTranscutaneous Electrical Acupoint Stimulation — noninvasive electrical stimulation at acupoints studied perioperatively for short‑term pain/ opioid‑sparing effects
inv-137: PENS (duplicate)
PENS duplicatePENS: percutaneous needle stimulation with variable session counts (many studies single or short series); immediate/short‑term effects reported
inv-138: PNS definition
PNS definitionPercutaneous Peripheral Nerve Stimulation — percutaneous or implantable leads placed near peripheral nerves for chronic or postoperative pain; recent trials describe 60‑day courses
inv-139: PENFS definition
PENFS definitionPercutaneous Electrical Nerve Field Stimulation (PENFS): auricular/field stimulation with limited evidence and preliminary neuroimaging findings
inv-140: PEMF / PES definition
PEMF/PES definitionPulsed Electromagnetic Field (PEMF) / Pulsed Electrical Stimulation (PES): noninvasive electromagnetic therapies studied for OA, postoperative recovery and CLBP with heterogeneous evidence
Restorative neurostimulation (ReActiv8)Implantable system targeting multifidus to treat refractory mechanical CLBP by delivering restorative stimulation sessions twice daily; trial populations required >90 days failed conservative care
inv-142: Pulsed electromagnetic field therapy (PEMF) definition
PEMF definition duplicatePulsed electromagnetic field therapy: noninvasive application intended to reduce pain/swelling and improve function in OA and postoperative settings; regimens vary (hours/day for weeks)
inv-143: Scrambler Therapy (ST) definition
Scrambler Therapy duplicateNoninvasive electro‑analgesia delivering synthetic 'non‑pain' information via cutaneous electrodes; trials commonly used 30–50 min sessions over ~10 working days
TLNS / PoNS definitionTranslingual stimulation (PoNS): portable device delivering stimulation to dorsal tongue surface combined with PT to treat balance/gait deficits; evidence limited and mixed
inv-146: NMES definition (duplicate)
NMES duplicate 2NMES devices: transcutaneous stimulators used to produce muscle contraction for rehabilitation; referenced product code IPF for device searches
inv-147: IFT definition (duplicate)
IFT duplicate 2IFT: interferential currents applied transcutaneously; studies insufficient to support safety/efficacy for musculoskeletal pain overall
inv-148: TENS devices (FDA product codes)
TENS device product codesFDA product codes referenced for TENS devices include GZJ, NUH, NGX; TENS devices are Class II
Supply examplesHCPCS/DME codes and supplies (A4438, A4543, A4595, E0720, E0730) listed in coding section
Restorative Neurostimulation duplicateImplantable restorative neurostimulation (ReActiv8) targets multifidus dysfunction; indicated for adults failing medical therapy and PT and not candidates for spine surgery
inv-150: Restorative neurostimulation (duplicate)
Restorative neurostimulation duplicate 2ReActiv8 approved via PMA; device programming delivers twice‑daily sessions; trials required >90 days failed conservative care
Percutaneous PNS definition duplicatePercutaneous peripheral nerve stimulation: short‑term (e.g., 60‑day) percutaneous lead treatments for chronic or postoperative neuropathic pain with RCTs and case series cited
FES generalFunctional electrical stimulation applied to legs evaluated for cardiopulmonary function and QOL (CHF trials) and for ambulation improvement (foot drop/hemiplegia), with variable trial designs
Device listingsFDA device listings referenced for FES product searches